WO2016158212A1 - Composition alimentaire contenant du resvératrol et du nicotinamide mononucléotide - Google Patents

Composition alimentaire contenant du resvératrol et du nicotinamide mononucléotide Download PDF

Info

Publication number
WO2016158212A1
WO2016158212A1 PCT/JP2016/056943 JP2016056943W WO2016158212A1 WO 2016158212 A1 WO2016158212 A1 WO 2016158212A1 JP 2016056943 W JP2016056943 W JP 2016056943W WO 2016158212 A1 WO2016158212 A1 WO 2016158212A1
Authority
WO
WIPO (PCT)
Prior art keywords
food composition
blood
resveratrol
composition according
nicotinamide
Prior art date
Application number
PCT/JP2016/056943
Other languages
English (en)
Japanese (ja)
Inventor
めぐみ 田中
和之 児玉
Original Assignee
新興和製薬株式会社
株式会社天真堂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 新興和製薬株式会社, 株式会社天真堂 filed Critical 新興和製薬株式会社
Priority to JP2017509446A priority Critical patent/JP6545256B2/ja
Publication of WO2016158212A1 publication Critical patent/WO2016158212A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids

Definitions

  • the present invention relates to a food composition containing resveratrol and nicotinamide mononucleotide.
  • lifestyle-related diseases such as obesity, hyperlipidemia, diabetes and hypertension.
  • lifestyle-related diseases have genetic elements, they are mainly caused by disordered lifestyles in daily life. Factors such as diet, exercise, drinking, smoking and stress are closely related to lifestyle-related diseases.
  • Factors such as diet, exercise, drinking, smoking and stress are closely related to lifestyle-related diseases.
  • dietary habits that consume high-calorie, high-fat foods have become commonplace. It is thought to have a big influence. Therefore, in order to prevent lifestyle-related diseases or cure them while the symptoms are mild and maintain health, it is important to feed a diet with a well-balanced nutritional balance.
  • Resveratrol is a type of stilbenoid polyphenol that functions as phytoalexin in some plants and is also found in grape skins, red wine, peanut skins, itadori, gnemon, etc. .
  • Resveratrol is known for its various physiological functions such as life-spanning action, female hormone action, antioxidant action, tyrosinase activity inhibitory action, antibacterial action, metabolic syndrome improving action, neuroprotective action, It is a functional ingredient that has attracted a great deal of attention.
  • Non- Patent Documents 1 and 2 Clinical studies on the effectiveness of resveratrol have reported improvement in vasodilator response, prevention of arteriosclerosis, and prevention of dementia by increasing cerebral blood flow in subjects with high blood pressure.
  • Non-patent Document 3 since a decrease in blood growth factor IGF-1 and its binding protein IGFBP-3 has been observed, the possibility of reducing the risk of breast cancer and lung cancer has been reported (Non-patent Document 3).
  • reports have been made on the energy consumption, metabolic rate, blood glucose level, blood pressure reduction and the like of obese men (Non-patent Document 4).
  • compositions containing resveratrol have been reported.
  • a pharmaceutical composition containing maltitol and resveratrol for the prevention and / or treatment of liver dysfunction (Patent Document 1). ), A metabolic promoter composition comprising two resveratrol derivatives having a predetermined structure as an active ingredient (Patent Document 2), a blood pressure-lowering agent containing transresveratrol in a plant extract containing ⁇ -viniferin ( Patent Document 3), resveratrol obtained by extraction with a polar solvent having 1 to 5 carbon atoms from buds and vines of plants belonging to European grape genus (Vitis Vinifera) and / or American grapevine (Vitis Labrusca) 5 ⁇ -reductase inhibitor, hyaluronidase inhibitor, elastase inhibitor, fibroblast proliferating agent, coller Production promoter or lipase inhibitor (Patent Document 4), and active ingredient includes resveratrol or its
  • resveratrol has a physiological effect that is considered to be useful in preventing lifestyle-related diseases and maintaining health, that is, an antioxidant effect and a normalizing action of blood sugar level. Has been reported. Therefore, many food compositions containing resveratrol are on the market in expectation of the effect of such physiological action.
  • an object of the present invention is to provide a resveratrol-containing food composition that is effective in preventing and improving lifestyle-related diseases and maintaining a healthy body state.
  • resveratrol with nicotinamide mononucleotide, which is an intermediate metabolite involved in the biosynthesis of coenzyme NAD (nicotinamide adenine dinucleotide).
  • the present invention is a food composition containing resveratrol and nicotinamide mononucleotide.
  • the food composition of the present invention is capable of orienting each value of blood total cholesterol, low-density lipoprotein cholesterol, neutral fat, and uric acid exceeding the proper reference range in the normal direction. It is very effective in preventing and ameliorating the disease and maintaining a healthy body condition.
  • the food composition of the present invention is characterized by containing resveratrol and nicotinamide mononucleotide, and by using both in combination, total cholesterol in blood, low density lipoprotein cholesterol, neutral fat, and uric acid Effectively normalizes each value.
  • Resveratrol (chemical formula: C 14 H 12 O 3 ) contained in the food composition of the present invention is a compound represented by the following structural formula [Chemical Formula 1], and as described above, grape skin and red wine It is known as an antioxidant contained in peanut skin, itadori, gnemon, and the like.
  • Resveratrol used in the present invention includes resveratrol derivatives such as trans and cis isomers, trans-cis isomer mixtures, dimers, and methylated resveratrol. Usually, heat-stable trans isomers are used for health foods and the like.
  • Resveratrol may be synthetically prepared in addition to those prepared by extraction and purification from any starting material. Many methods for producing resveratrol have been reported.
  • styrene derivatives using 3,5-dihydroxybenzoic acid as a starting material protection of phenolic hydroxyl groups with acetyl groups, conversion to acid chlorides, and palladium catalysts.
  • There are known methods such as coupling with water, deprotection by hydrolysis, and hydrolyzing by Heck coupling of 3,5-diacetoxystyrene and p-acetoxyiodobenzene using a palladium catalyst.
  • resveratrol is marketed and those commercial items can be purchased and used.
  • Nicotinamide mononucleotide contained in the food composition of the present invention is a compound represented by the following structural formula [Chemical Formula 2], and generally NMN (Nicotinamide mononucleotide) And is known as an intermediate metabolite involved in the biosynthesis of the coenzyme NAD + . In vivo, it is produced in the NAD metabolic pathway by the liver tissue, that is, the pathway toward synthesis of nicotinamide adenine dinucleotide (NAD) from quinolinic acid via the kynurenine pathway. This point will be specifically described with reference to FIG.
  • NAD nicotinamide adenine dinucleotide
  • tryptophan when tryptophan is used as a starting material, tryptophan is converted into quinolinic acid (QA) via the kynurenine pathway, which is a tryptophan metabolic pathway, and further converted into nicotinic acid mononucleotide (NaMN).
  • QA quinolinic acid
  • NaMN nicotinic acid mononucleotide
  • nicotinic acid (Na) when nicotinic acid (Na) is used as a starting material, nicotinic acid is directly converted to NaMN. NaMN is then converted into NAD, nicotinamide (NaM), and nicotinamide mononucleotide by the NAD cycle via nicotinic acid adenine dinucleotide (NaAD).
  • Nicotinamide (NaM) is converted to nicotinamide mononucleotide by nicotinamide phosphoribosyltransferase (NAMPT), which is then converted by nicotinamide mononucleotide adenyltransferase (NMNAT) to produce NAD. Nicotinamide mononucleotide is also produced from nicotinamide riboside (NR).
  • NAMPT nicotinamide phosphoribosyltransferase
  • NMNAT nicotinamide mononucleotide adenyltransferase
  • Nicotinamide mononucleotide is also produced from nicotinamide riboside (NR).
  • Nicotinamide mononucleotide has two types of ⁇ isomers and ⁇ isomers as optical isomers, and ⁇ isomers are used in the present invention. Nicotinamide mononucleotide is prepared, for example, by synthesizing nicotinamide riboside from nicotinamide and ribose (see Bioorg. Med. Chem. Lett., 12, 1135-1137 (2002)), and then the 5-position hydroxyl group of the ribose moiety. It can be obtained by phosphorylation (see Chem. Comm., 1999, 729-730).
  • nicotinamide and L-ribose tetraacetate are dissolved in anhydrous acetonitrile, an excess amount of trimethylsilyl trifluorosulfonic acid is added under a nitrogen stream, and the mixture is stirred at room temperature and methanol is added.
  • the reaction solution whose reaction has been stopped is applied to a column filled with activated carbon, washed with distilled water, and eluted with methanol to recover the product.
  • nicotinamide mononucleotide is commercially available, and those commercially available products can be purchased and used.
  • the ratio of resveratrol and nicotinamide mononucleotide is not limited, but from the viewpoint of maximizing the effects of the present invention, It is preferable to adjust the blending ratio of both so that resveratrol is 1 to 100 parts by mass and nicotinamide mononucleotide is 1 to 25 parts by mass.
  • the food composition of the present invention further includes one or more selected from the group consisting of tryptophan and niacin (vitamin B3; generic name for nicotinic acid and nicotinamide) and metabolites thereof. It is preferable. Thereby, the effect of improving the neutral fat level in the blood is further enhanced. The reason for this enhancement is unclear, but it is thought that intracellular energy metabolism is related because tryptophan, niacin, and most of their metabolites function as coenzymes for in vivo redox reactions.
  • niacin examples include nicotinic acid adenine dinucleotide, nicotinic acid mononucleotide, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, nicotinamide riboside and ADP ribose.
  • the food composition of the present invention includes nutritional supplements, excipients, binders, dispersants, lubricants, disintegrants, emulsifiers, solubilizers, pH adjusters, antioxidants, taste
  • An improving agent or the like can be appropriately added within a range that does not impair the effects of the present invention.
  • Examples of the nutritional supplement component include amino acids, minerals, vitamins, coenzymes, plant extracts, collagen, elastin, peptides, mucopolysaccharides (hyaluronic acid, chondroitin, etc.) and the like.
  • excipient examples include lactose, sucrose, fructose, glucose, glucose hydrate, sucrose, purified sucrose, xylitol, sorbitol, mannitol, palatinose, reduced palatinose, powdered maltose, water candy, carmellose, dextrin, corn starch , Pregelatinized starch, partially pregelatinized starch, potato starch, corn starch, hydroxypropyl starch, amino acid, kaolin, silicic anhydride, silicic acid, aluminum silicate, sodium bicarbonate, calcium phosphate, calcium dihydrogen phosphate, calcium carbonate, oxidation Magnesium, aluminum hydroxide, fatty acid or salt thereof, fatty acid monoglyceride and diglyceride, various spirits, olive oil, soybean oil, corn oil, fatty oil, oil and fat, propylene glycol, Glycol, polyethylene glycol, glycerol and the like.
  • binder examples include crystalline cellulose, crystalline cellulose / carmellose sodium, methylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carmellose sodium, ethylcellulose , Carboxymethyl ethyl cellulose, hydroxyethyl cellulose, wheat starch, rice starch, corn starch, potato starch, pregelatinized starch, partially pregelatinized starch, hydroxypropyl starch, dextrin, pullulan, polyvinylpyrrolidone, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate Over copolymer RS, methacrylic acid copolymer L, methacrylic acid copolymer, polyvinyl acetal diethylamino acetate, polyvinyl alcohol, gum arabic, gum arabic powder,
  • dispersant or lubricant examples include magnesium stearate, calcium stearate, stearic acid, hydrous silicon dioxide, sucrose fatty acid ester, wheat starch, rice starch, corn starch, synthetic aluminum silicate, dry aluminum hydroxide gel, and metasilicic acid.
  • examples thereof include magnesium aluminate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, hydrogenated vegetable oil, polyethylene glycol, light anhydrous silicic acid, synthetic aluminum silicate, macrogol, talc and the like.
  • disintegrant examples include crystalline cellulose, methylcellulose, low-substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, wheat starch, rice starch, corn starch, potato starch, partially pregelatinized starch, Examples include hydroxypropyl starch, carboxymethyl starch sodium, tragacanth and the like.
  • emulsifier examples include soybean lecithin, sucrose fatty acid ester, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, monopalmitic acid
  • examples include sorbitan, sorbitan monolaurate, polysorbate, glyceryl monostearate, sodium lauryl sulfate, lauromacrogol and the like.
  • solubilizer examples include sodium phosphate, polysorbates
  • the pH adjuster includes citric acid, sodium citrate, acetic acid, tartaric acid, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, lactic acid
  • examples of the antioxidant include ascorbic acid, erythorbic acid, catechin
  • examples of the taste improver include various fruit juices and vegetable extracts.
  • cranberry juice orange juice, acerola juice, grape juice, apple juice, peach juice, muscat juice, pineapple juice, lychee juice, raspberry juice, pomegranate juice, kiwifruit juice, cherry juice, blueberry
  • beverage substrates such as fruit juice, lotus cup juice, grapefruit juice, and lime juice.
  • the method for producing the food composition of the present invention is not particularly limited, and a general production method used for producing the food composition may be appropriately selected according to the form of the food composition.
  • the form of the food composition is a powder, it can be produced by uniformly kneading resveratrol, nicotinamide mononucleotide, and other components blended as necessary. What is necessary is just to determine the compounding quantity of each component suitably.
  • resveratrol and nicotinamide mononucleotide which are essential components, are commercially available and can be obtained commercially.
  • nicotinamide mononucleotide the quality control system and mass production system of nicotinamide mononucleotide have been established in recent years, and supply as a food composition raw material has become possible. It has been confirmed.
  • the food composition of the present invention is provided as various foods and beverages. In that case, it can be processed and provided in the same form as general dietary supplements, that is, powders, tablets, pills, granules, hard capsules, soft capsules, jellies, liquids, pastes and the like.
  • the daily intake amount of resveratrol contained in the food composition is usually 1 mg to 1000 mg, preferably 1 mg to 500 mg, more preferably 1 mg to 100 mg. is there. If the amount is less than 1 mg, the effect of the present invention may not be obtained. On the other hand, if the amount is more than 1000 mg, the obtained effect is not particularly changed, which is economically disadvantageous.
  • the food composition of the present invention is useful in preventing and improving lifestyle-related diseases, but can be preferably used as a food composition for reducing total cholesterol in blood. That is, by ingesting the food composition of the present invention, total cholesterol in the blood exceeding the appropriate reference range can be reduced.
  • Cholesterol is an important component that is made in the liver and forms cell membranes and generates bile acids and sex hormones that help digest fat in the intestines. Increased chance of causing arteriosclerosis.
  • the incidence of ischemic heart diseases such as myocardial infarction is said to correlate with blood cholesterol.
  • the total cholesterol level in the blood is 130 to 219 mg / dL, but as shown in the examples described later, the food composition of the present invention is continuously ingested for a certain period of time. By doing so, the total cholesterol value higher than the reference range can be reduced.
  • the food composition of the present invention can be preferably used as a food composition for reducing low specific gravity lipoprotein cholesterol in blood. That is, by ingesting the food composition of the present invention, low-density lipoprotein cholesterol (LDL cholesterol) in blood exceeding the appropriate reference range can be reduced. Low density lipoprotein cholesterol is transported from the liver to whole body tissues, but if it is too much, it accumulates in the arterial wall and promotes arteriosclerosis, so it is also called bad cholesterol.
  • the low specific gravity lipoprotein cholesterol level in the blood is approximately 65 to 139 mg / dL as a rough standard, but as shown in the examples described later, the food composition of the present invention is continuously added. By ingesting for a certain period of time, a low specific gravity lipoprotein cholesterol level higher than the reference range can be reduced.
  • the food composition of the present invention can be preferably used as a food composition for reducing neutral fat in blood. That is, by ingesting the food composition of the present invention, it is possible to reduce the neutral fat in the blood that exceeds the appropriate reference range.
  • Neutral fat is absorbed in the small intestine after food intake and enters the blood to be used as an energy source, but if it is too much, it can cause obesity, fatty liver, diabetes, etc. Because it leads to an increase, it promotes arteriosclerosis and becomes a base for stroke and heart disease.
  • the blood neutral fat level is 30 to 149 mg / dL as a reference range.
  • the food composition of the present invention is continuously applied for a certain period of time. By ingesting, a neutral fat value higher than the reference range can be reduced.
  • the food composition of the present invention can be preferably used as a food composition for reducing uric acid in blood. That is, by ingesting the food composition of the present invention, uric acid in the blood exceeding the appropriate reference range can be reduced.
  • Uric acid is a waste product made by decomposing DNA constituting the gene and ATP responsible for energy, but if it is too much, it can cause gout, kidney damage, urinary calculus, etc., metabolic syndrome, hypertension, lipid It becomes easy to combine life-style related diseases such as abnormalities and diabetes.
  • the uric acid level in the blood is roughly set as the reference value range for males 3.8 to 7.0 mg / dL and females 2.5 to 7.0 mg / dL. As described above, by continuously ingesting the food composition of the present invention for a certain period, it is possible to reduce the uric acid value higher than the reference value range.
  • the food composition of the present invention can be taken regardless of gender.
  • it is suitably applied to middle-aged and elderly people whose blood total cholesterol, low-density lipoprotein cholesterol, neutral fat, and uric acid values exceed the appropriate reference range.
  • the intake period is not limited, but in order to make the total cholesterol, low density lipoprotein cholesterol, neutral fat, and uric acid values that exceed the appropriate reference range normal, take them for a long period of time. It is preferable to take it continuously every day for at least about 4 weeks.
  • Example 1 440 mg of excipients (starch, calcium stearate, fine silicon dioxide) are added to 20 mg of resveratrol and 20 mg of ⁇ -nicotinamide mononucleotide and kneaded homogeneously, and the resulting product is filled into a commercially available hard capsule This produced a hard capsule.
  • excipients starch, calcium stearate, fine silicon dioxide
  • Example 2 To resveratrol 20 mg, ⁇ -nicotinamide mononucleotide 20 mg, and niacinamide 120 mg, 340 mg of excipients (starch, calcium stearate, fine silicon dioxide) were added and kneaded uniformly, and the resulting product was commercially available. A hard capsule was prepared by filling the hard capsule.
  • each hard capsule prepared in Examples 1 and 2 was given to 3 subjects (50s) each with a high total blood cholesterol level, once a day with 2 capsules, water or lukewarm water once a day (dinner It was ingested continuously for 4 weeks (28 days) at the frequency of (before).
  • each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high total blood cholesterol level once daily with 2 capsules, water, or lukewarm water. It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
  • each hard capsule prepared in Examples 1 and 2 was given to 3 subjects (50s) each with high blood low density lipoprotein cholesterol, once daily with 2 capsules, water or lukewarm water. It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
  • each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with high low-density lipoprotein cholesterol in the blood each day with 2 capsules, water, or lukewarm water for 1 day. It was ingested continuously at a frequency of once (before dinner) for 4 weeks (28 days).
  • LDL cholesterol low density lipoprotein cholesterol
  • each of the hard capsules prepared in Examples 1 and 2 was given to 3 subjects (in their 50s) each with a high blood neutral fat level once a day with 2 capsules, water or lukewarm water at a time ( It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
  • each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high blood neutral fat level, with 2 capsules, water or lukewarm water per day. It was ingested continuously for 4 weeks (28 days) at a frequency of twice (before dinner).
  • each hard capsule prepared in Example 1 was given to two subjects (in their 50s) with high blood uric acid levels once a day (before dinner) with 2 capsules, water or lukewarm water each time. For 4 weeks (28 days).
  • each hard capsule prepared in Comparative Examples 1 and 2 was given to two subjects (in their 50s) each with a high blood uric acid level once a day with 2 capsules, water or lukewarm water at a time ( It was ingested continuously for 4 weeks (28 days) at a frequency of (before dinner).
  • Example 1 As can be seen from the results shown in Table 4, when the hard capsule prepared in Example 1 was ingested, it was recognized that the uric acid value significantly decreased. On the other hand, when the hard capsules prepared in Comparative Examples 1 and 2 were ingested, an increase in the uric acid level was observed in both cases. From this, the food composition of Example 1 containing resveratrol and nicotinamide mononucleotide has an effect that cannot be predicted from the food compositions of Comparative Examples 1 and 2, that is, an effect of reducing the concentration of uric acid in blood. It was confirmed.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention vise à fournir une composition alimentaire contenant du resvératrol, qui soit efficace dans la prévention de maladies liées au mode de vie et dans l'atténuation des symptômes desdites maladies ainsi que dans le maintien d'une bonne condition physique. La solution à ce problème réside dans une composition alimentaire contenant du resvératrol et du nicotinamide mononucléotide.
PCT/JP2016/056943 2015-03-31 2016-03-07 Composition alimentaire contenant du resvératrol et du nicotinamide mononucléotide WO2016158212A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017509446A JP6545256B2 (ja) 2015-03-31 2016-03-07 レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015071150 2015-03-31
JP2015-071150 2015-03-31

Publications (1)

Publication Number Publication Date
WO2016158212A1 true WO2016158212A1 (fr) 2016-10-06

Family

ID=57006686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/056943 WO2016158212A1 (fr) 2015-03-31 2016-03-07 Composition alimentaire contenant du resvératrol et du nicotinamide mononucléotide

Country Status (2)

Country Link
JP (1) JP6545256B2 (fr)
WO (1) WO2016158212A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062311A1 (fr) 2015-10-07 2017-04-13 Huizenga Joel Réinitialisation de voies biologiques de défense contre et de réparation d'une détérioration causée par le vieillissement humain
WO2019044348A1 (fr) * 2017-08-30 2019-03-07 アサヒグループホールディングス株式会社 Composition pour diminuer le taux d'acide urique sérique
CN109589309A (zh) * 2017-09-30 2019-04-09 浙江嘉华化工有限公司 烟酰胺核糖微囊的制备方法
CN112089705A (zh) * 2020-09-28 2020-12-18 深圳雾件科技有限公司 一种烟酰胺单核苷酸微囊及其制备方法
CN112155186A (zh) * 2020-11-11 2021-01-01 北京斯利安药业有限公司 一种抗氧化和/或延缓衰老的组合物、其应用和产品
CN112515070A (zh) * 2020-11-11 2021-03-19 云南爱尔康生物技术有限公司 一种含虾青素、牛磺酸、烟酰胺单核苷酸及电解质的运动饮料及制作方法
CN113832204A (zh) * 2021-09-22 2021-12-24 杭州吾尾科技有限公司 Nmn的制备方法及含nmn的犬猫抗衰老保健品配方
JP7026422B1 (ja) 2021-06-30 2022-02-28 ドリームパワー株式会社 飲料
WO2022101501A1 (fr) * 2020-11-16 2022-05-19 Scandibio Therapeutics Ab Substances pour le traitement d'hyperuricémie
JP7168279B1 (ja) * 2021-12-20 2022-11-09 ドリームパワー株式会社 液体組成物およびサーチュイン活性化用組成物
JP7287587B1 (ja) * 2023-01-18 2023-06-06 大正製薬株式会社 固形組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113181205B (zh) * 2021-04-19 2023-07-14 苏州人本药业有限公司 包括nmn的药物组合物及其应用
TWI832388B (zh) * 2022-08-22 2024-02-11 睿創健康股份有限公司 美白保健組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006001982A2 (fr) * 2004-06-04 2006-01-05 Washington University Methodes et compositions de traitement de neuropathies
WO2007008548A2 (fr) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methodes et compositions associees pour le traitement ou la prevention de l'obesite, de troubles d'insulino-resistance et de troubles associes aux mitochondries
US20100254962A1 (en) * 2007-10-24 2010-10-07 Karl Zehethofer Functional drink

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006001982A2 (fr) * 2004-06-04 2006-01-05 Washington University Methodes et compositions de traitement de neuropathies
WO2007008548A2 (fr) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methodes et compositions associees pour le traitement ou la prevention de l'obesite, de troubles d'insulino-resistance et de troubles associes aux mitochondries
US20100254962A1 (en) * 2007-10-24 2010-10-07 Karl Zehethofer Functional drink

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PALSAMY P. ET AL.: "Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats", BIOMED. PHARMACOTHER., vol. 62, no. 9, November 2008 (2008-11-01), pages 598 - 605, XP025571995 *
SHI Y. W. ET AL.: "Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice", MOL. NUTR. FOOD RES., vol. 56, no. 9, September 2012 (2012-09-01), pages 1433 - 1444, XP055319533 *
SHINKOWA TRADING CO., LTD.: "NMN Haigo Supplement", PRESS RELEASE, 22 April 2015 (2015-04-22), XP055319534, Retrieved from the Internet <URL:https://www.atpress.ne.jp/news/print/window/popup/pr_id/60629/> [retrieved on 20160509] *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062311A1 (fr) 2015-10-07 2017-04-13 Huizenga Joel Réinitialisation de voies biologiques de défense contre et de réparation d'une détérioration causée par le vieillissement humain
JP2018530614A (ja) * 2015-10-07 2018-10-18 ハイゼンガ，ジョエル ヒト老化から防御するためおよびそれによる劣化を修復するための生物学的経路のリセット
EP3359259A4 (fr) * 2015-10-07 2019-04-24 Huizenga, Joel Réinitialisation de voies biologiques de défense contre et de réparation d'une détérioration causée par le vieillissement humain
WO2019044348A1 (fr) * 2017-08-30 2019-03-07 アサヒグループホールディングス株式会社 Composition pour diminuer le taux d'acide urique sérique
JP6492236B1 (ja) * 2017-08-30 2019-03-27 アサヒグループホールディングス株式会社 血清尿酸値低減用組成物
US11173143B2 (en) 2017-08-30 2021-11-16 Asahi Group Holdings, Ltd. Composition for decreasing serum uric acid level
CN109589309A (zh) * 2017-09-30 2019-04-09 浙江嘉华化工有限公司 烟酰胺核糖微囊的制备方法
CN112089705A (zh) * 2020-09-28 2020-12-18 深圳雾件科技有限公司 一种烟酰胺单核苷酸微囊及其制备方法
CN112515070A (zh) * 2020-11-11 2021-03-19 云南爱尔康生物技术有限公司 一种含虾青素、牛磺酸、烟酰胺单核苷酸及电解质的运动饮料及制作方法
CN112155186A (zh) * 2020-11-11 2021-01-01 北京斯利安药业有限公司 一种抗氧化和/或延缓衰老的组合物、其应用和产品
WO2022101501A1 (fr) * 2020-11-16 2022-05-19 Scandibio Therapeutics Ab Substances pour le traitement d'hyperuricémie
EP4000611A1 (fr) * 2020-11-16 2022-05-25 ScandiBio Therapeutics AB Substances pour le traitement de l'hyperuricémie
JP7026422B1 (ja) 2021-06-30 2022-02-28 ドリームパワー株式会社 飲料
JP2023006363A (ja) * 2021-06-30 2023-01-18 ドリームパワー株式会社 飲料
CN113832204A (zh) * 2021-09-22 2021-12-24 杭州吾尾科技有限公司 Nmn的制备方法及含nmn的犬猫抗衰老保健品配方
JP7168279B1 (ja) * 2021-12-20 2022-11-09 ドリームパワー株式会社 液体組成物およびサーチュイン活性化用組成物
JP7287587B1 (ja) * 2023-01-18 2023-06-06 大正製薬株式会社 固形組成物

Also Published As

Publication number Publication date
JP6545256B2 (ja) 2019-07-17
JPWO2016158212A1 (ja) 2018-02-22

Similar Documents

Publication Publication Date Title
WO2016158212A1 (fr) Composition alimentaire contenant du resvératrol et du nicotinamide mononucléotide
US11219590B2 (en) Anti-aging agent and anti-aging method
EP3513796A1 (fr) Agent améliorant les troubles du sommeil, et procédé d&#39;amélioration des troubles du sommeil
EP3850954A1 (fr) Agent anti-âge et procédé anti-âge
EP3513795B1 (fr) Agent améliorant la fonction visuelle, et procédé d&#39;amélioration de la fonction visuelle
JP5121308B2 (ja) メタボリックシンドロームの予防、改善または治療組成物
JP2009543883A (ja) ケルセチン含有組成物
JP6335508B2 (ja) 成長ホルモン分泌促進剤
KR20070039924A (ko) 석류액, 석류액 분말 및 분말 생산 공정
JP2008297209A (ja) 脂質代謝改善組成物
KR20140090453A (ko) 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물
EP4122536A1 (fr) Promoteur de production de coenzyme q et procédé de promotion de production de coenzyme q
JP2005185188A (ja) アセロラ処理物およびｌ−カルニチン含有組成物
JP5545692B2 (ja) キサンチンオキシダーゼ阻害剤及び血漿中尿酸値低下剤
JP2007000081A (ja) 脂質代謝改善用食品
KR20130112236A (ko) 부티르산 나트륨을 유효성분으로 함유하는 고 글루코즈로 유도된 염증 억제용 조성물
JP2009298759A (ja) α‐アミラーゼ阻害剤
JP2005139093A (ja) グルコース吸収阻害剤およびその製造方法
KR20170065117A (ko) 3-카페오일-4-디히드로카페오일 퀴닉산을 유효성분으로 함유하는 혈관질환의 예방, 개선 또는 치료용 조성물
EP4309515A1 (fr) Composition favorisant la sécrétion de glp-1
JP2011132173A (ja) キサンチンオキシダーゼ阻害剤及び尿酸生成阻害剤
JP2022098492A (ja) 脳内のミトコンドリア生合成能向上用組成物
JP5406085B2 (ja) ヘリコバクター・ピロリ接着抑制剤
JP2009051751A (ja) 筋肉細胞糖輸送促進作用組成物
JP2009023948A (ja) ドーパミン抑制剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16772096

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017509446

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09.01.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16772096

Country of ref document: EP

Kind code of ref document: A1